DILI Conference XIV: Predicting Serious Drug-Induced Liver Injury in Patients: Who Gets it? Who Doesn’t? Why?
Wednesday, March 19, 2014 –
Thursday, March 20, 2014
7:30 AM – 3:00 PM
Marriott Inn & Conference Center
University of Maryland
3501 University Blvd.
East Hyattsville, Maryland 20783
Who Gets It? Who Doesn’t? Why?
Serious drug-induced liver injury (SDILI) is a major problem for drug development and clinical care. We need a new understanding to identify especially susceptible patients, and a path forward to solve hepatotoxicity problems that affect pharmaceutical industry protocols, government regulatory bodies, academic consultants, and physicians who use drugs to provide patient care in the US and worldwide. This academic-industry-government international conference will discuss new findings and thinking about DILI, including presentations by experts in clinical hepatology, toxicology, and other fields, and lively discussions with all registrants. We look forward to your participation!
Organizers: John R. Senior and Lana Pauls
The program is co-sponsored by the Food and Drug Administration/Center for Drug Evaluation and Research (FDA/CDER), the Critical Path Institute (C-Path), and the Pharmaceutical Research and Manufacturers of America (PhRMA). The program is endorsed by the National Institutes of Health (NIH) the Drug-Induced Liver Injury Network (DILIN), and the American Association for the Study of Liver Diseases (AASLD).